Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission

Eneida Nemecek, Kristin Ellis, Wensheng He, Nancy J. Bunin, Rajinder S. Bajwa, Alexandra Cheerva, Mitchell S. Cairo, Christopher Dvorak, Michel Duval, Stella Davies, Mary Eapen, Thomas G. Gross, Ayad A. Hussein, Margaret L. MacMillan, Parinda A. Mehta, Michael A. Pulsipher, Adriana Seber, Ann E. Woolfrey, Haydar A. Frangoul, Paul A. Carpenter

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We conducted a retrospective study of 155 children who underwent unrelated donor hematopoietic cell transplantation (HCT) between 1990 and 2005 for acute lymphoblastic leukemia in third remission. The median patient age was 11 years, the median time from diagnosis to first relapse was 36 months, and the median time from first relapse to second relapse was 26 months. Stem cell sources were bone marrow (n = 115), peripheral blood (n = 11), and cord blood (n = 29). All patients received a myeloablative pretransplantation conditioning regimen. The 5-year estimates of leukemia-free survival, relapse, and nonrelapse mortality were 30%, 25%, and 45%, respectively. In multivariate analysis, the only risk factor associated with relapse was the interval between the first relapse and the second relapse. Second relapses occurring >26 months from the first relapse were associated with lower risk for post-HCT relapse compared with second relapses occurring at ≤26 months (relative risk, 0.4; P =.01). Relapse risk was lowest when late second relapse was preceded by late first relapse (>36 months from diagnosis), as demonstrated by a 3-year relapse rate of 9% (P =.0009). Our data indicate that long-term leukemia-free survival can be achieved in children with acute lymphoblastic leukemia in third remission using unrelated donor HCT, especially when the second relapse occurs late.

Original languageEnglish (US)
Pages (from-to)1833-1840
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume17
Issue number12
DOIs
StatePublished - Dec 2011

Fingerprint

Unrelated Donors
Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Leukemia
Survival

Keywords

  • Advanced ALL
  • BMT
  • HCT
  • Nonrelapse mortality

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission. / Nemecek, Eneida; Ellis, Kristin; He, Wensheng; Bunin, Nancy J.; Bajwa, Rajinder S.; Cheerva, Alexandra; Cairo, Mitchell S.; Dvorak, Christopher; Duval, Michel; Davies, Stella; Eapen, Mary; Gross, Thomas G.; Hussein, Ayad A.; MacMillan, Margaret L.; Mehta, Parinda A.; Pulsipher, Michael A.; Seber, Adriana; Woolfrey, Ann E.; Frangoul, Haydar A.; Carpenter, Paul A.

In: Biology of Blood and Marrow Transplantation, Vol. 17, No. 12, 12.2011, p. 1833-1840.

Research output: Contribution to journalArticle

Nemecek, E, Ellis, K, He, W, Bunin, NJ, Bajwa, RS, Cheerva, A, Cairo, MS, Dvorak, C, Duval, M, Davies, S, Eapen, M, Gross, TG, Hussein, AA, MacMillan, ML, Mehta, PA, Pulsipher, MA, Seber, A, Woolfrey, AE, Frangoul, HA & Carpenter, PA 2011, 'Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission', Biology of Blood and Marrow Transplantation, vol. 17, no. 12, pp. 1833-1840. https://doi.org/10.1016/j.bbmt.2011.05.014
Nemecek, Eneida ; Ellis, Kristin ; He, Wensheng ; Bunin, Nancy J. ; Bajwa, Rajinder S. ; Cheerva, Alexandra ; Cairo, Mitchell S. ; Dvorak, Christopher ; Duval, Michel ; Davies, Stella ; Eapen, Mary ; Gross, Thomas G. ; Hussein, Ayad A. ; MacMillan, Margaret L. ; Mehta, Parinda A. ; Pulsipher, Michael A. ; Seber, Adriana ; Woolfrey, Ann E. ; Frangoul, Haydar A. ; Carpenter, Paul A. / Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission. In: Biology of Blood and Marrow Transplantation. 2011 ; Vol. 17, No. 12. pp. 1833-1840.
@article{88dd3fa2e5c14da0bef02ff640f84cee,
title = "Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission",
abstract = "We conducted a retrospective study of 155 children who underwent unrelated donor hematopoietic cell transplantation (HCT) between 1990 and 2005 for acute lymphoblastic leukemia in third remission. The median patient age was 11 years, the median time from diagnosis to first relapse was 36 months, and the median time from first relapse to second relapse was 26 months. Stem cell sources were bone marrow (n = 115), peripheral blood (n = 11), and cord blood (n = 29). All patients received a myeloablative pretransplantation conditioning regimen. The 5-year estimates of leukemia-free survival, relapse, and nonrelapse mortality were 30{\%}, 25{\%}, and 45{\%}, respectively. In multivariate analysis, the only risk factor associated with relapse was the interval between the first relapse and the second relapse. Second relapses occurring >26 months from the first relapse were associated with lower risk for post-HCT relapse compared with second relapses occurring at ≤26 months (relative risk, 0.4; P =.01). Relapse risk was lowest when late second relapse was preceded by late first relapse (>36 months from diagnosis), as demonstrated by a 3-year relapse rate of 9{\%} (P =.0009). Our data indicate that long-term leukemia-free survival can be achieved in children with acute lymphoblastic leukemia in third remission using unrelated donor HCT, especially when the second relapse occurs late.",
keywords = "Advanced ALL, BMT, HCT, Nonrelapse mortality",
author = "Eneida Nemecek and Kristin Ellis and Wensheng He and Bunin, {Nancy J.} and Bajwa, {Rajinder S.} and Alexandra Cheerva and Cairo, {Mitchell S.} and Christopher Dvorak and Michel Duval and Stella Davies and Mary Eapen and Gross, {Thomas G.} and Hussein, {Ayad A.} and MacMillan, {Margaret L.} and Mehta, {Parinda A.} and Pulsipher, {Michael A.} and Adriana Seber and Woolfrey, {Ann E.} and Frangoul, {Haydar A.} and Carpenter, {Paul A.}",
year = "2011",
month = "12",
doi = "10.1016/j.bbmt.2011.05.014",
language = "English (US)",
volume = "17",
pages = "1833--1840",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission

AU - Nemecek, Eneida

AU - Ellis, Kristin

AU - He, Wensheng

AU - Bunin, Nancy J.

AU - Bajwa, Rajinder S.

AU - Cheerva, Alexandra

AU - Cairo, Mitchell S.

AU - Dvorak, Christopher

AU - Duval, Michel

AU - Davies, Stella

AU - Eapen, Mary

AU - Gross, Thomas G.

AU - Hussein, Ayad A.

AU - MacMillan, Margaret L.

AU - Mehta, Parinda A.

AU - Pulsipher, Michael A.

AU - Seber, Adriana

AU - Woolfrey, Ann E.

AU - Frangoul, Haydar A.

AU - Carpenter, Paul A.

PY - 2011/12

Y1 - 2011/12

N2 - We conducted a retrospective study of 155 children who underwent unrelated donor hematopoietic cell transplantation (HCT) between 1990 and 2005 for acute lymphoblastic leukemia in third remission. The median patient age was 11 years, the median time from diagnosis to first relapse was 36 months, and the median time from first relapse to second relapse was 26 months. Stem cell sources were bone marrow (n = 115), peripheral blood (n = 11), and cord blood (n = 29). All patients received a myeloablative pretransplantation conditioning regimen. The 5-year estimates of leukemia-free survival, relapse, and nonrelapse mortality were 30%, 25%, and 45%, respectively. In multivariate analysis, the only risk factor associated with relapse was the interval between the first relapse and the second relapse. Second relapses occurring >26 months from the first relapse were associated with lower risk for post-HCT relapse compared with second relapses occurring at ≤26 months (relative risk, 0.4; P =.01). Relapse risk was lowest when late second relapse was preceded by late first relapse (>36 months from diagnosis), as demonstrated by a 3-year relapse rate of 9% (P =.0009). Our data indicate that long-term leukemia-free survival can be achieved in children with acute lymphoblastic leukemia in third remission using unrelated donor HCT, especially when the second relapse occurs late.

AB - We conducted a retrospective study of 155 children who underwent unrelated donor hematopoietic cell transplantation (HCT) between 1990 and 2005 for acute lymphoblastic leukemia in third remission. The median patient age was 11 years, the median time from diagnosis to first relapse was 36 months, and the median time from first relapse to second relapse was 26 months. Stem cell sources were bone marrow (n = 115), peripheral blood (n = 11), and cord blood (n = 29). All patients received a myeloablative pretransplantation conditioning regimen. The 5-year estimates of leukemia-free survival, relapse, and nonrelapse mortality were 30%, 25%, and 45%, respectively. In multivariate analysis, the only risk factor associated with relapse was the interval between the first relapse and the second relapse. Second relapses occurring >26 months from the first relapse were associated with lower risk for post-HCT relapse compared with second relapses occurring at ≤26 months (relative risk, 0.4; P =.01). Relapse risk was lowest when late second relapse was preceded by late first relapse (>36 months from diagnosis), as demonstrated by a 3-year relapse rate of 9% (P =.0009). Our data indicate that long-term leukemia-free survival can be achieved in children with acute lymphoblastic leukemia in third remission using unrelated donor HCT, especially when the second relapse occurs late.

KW - Advanced ALL

KW - BMT

KW - HCT

KW - Nonrelapse mortality

UR - http://www.scopus.com/inward/record.url?scp=81255161748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81255161748&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2011.05.014

DO - 10.1016/j.bbmt.2011.05.014

M3 - Article

VL - 17

SP - 1833

EP - 1840

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -